Please assess the completion status of the following clinical trial:

Trial Title: Epanova® for Lowering Very High Triglycerides II (EVOLVE II)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Understanding of the study procedures, willingness to adhere to the study schedule, and agreement to participate in the study by giving written informed consent prior to screening;~2. Willing to use an appropriate and effective method of contraception;~3. Qualifying (average of Visit 1 or 1a + Visit 2 + Visit 2a \[repeat measurement\]) serum TG ≥500 mg/dL (6 mMol/L) and \<2500 mg/dL (28 mMol/L);~4. Body mass index ≥20 kg/m2;~5. Untreated dyslipidemia or dyslipidemia treated with a statin, CAI, or statin-CAI combination that has been stable for 6 weeks prior to randomization; and~6. Willingness to maintain current physical activity level and follow the TLC diet throughout the study.~Exclusion Criteria:~1. Allergy or intolerance to omega-3 fatty acids, omega-3-acid ethyl esters, or fish;~2. Known lipoprotein lipase impairment;~3. Known non-responder to omega-3 or fenofibrate therapy;~4. Use of any prescription medications containing EPA and/or DHA (eg, Lovaza® or Vascepa®) within 8 weeks prior to randomization. Up to 1 g capsule/day of an omega-3 dietary supplement will be permitted;~5. Unable to discontinue use of bile acid sequestrants, fibrates or niacin (other than niacin-containing vitamins \<200 mg), or any supplement used to alter lipid metabolism including but not limited to dietary fiber supplements, red rice yeast supplements, garlic supplements, soy isoflavone supplements, sterol/stanol products, or policosanols at screening;~6. Use of tamoxifen, estrogens, or progestins that has not been stable for \>4 weeks at screening or is unstable prior to randomization;~7. Use of oral or injected corticosteroids or anabolic steroids prior to randomization;~8. History of hospitalization for pancreatitis in the last 5 years;~9. Uncontrolled diabetes (hemoglobin A1c \[HbA1c\] \>10%);~10. Uncontrolled hypothyroidism or thyroid-stimulating hormone (TSH) \>5 mIU/L;~11. History of cancer (other than basal cell carcinoma) in the past 2 years;~12. Cardiovascular event (ie, myocardial infarction, acute coronary syndrome, new onset angina, stroke, transient heart attack, unstable congestive heart failure requiring a change in treatment), revascularization procedure or vascular surgery within 6 months of randomization;~13. Use of simvastatin 80 mg or Vytorin 10/80 mg;~14. Recent history (within 6 months of randomization) of significant nephrotic syndrome, pulmonary, hepatic, biliary, gastrointestinal, or immunologic disease;~15. Poorly controlled hypertension (systolic blood pressure ≥180 mmHg and/or diastolic blood pressure ≥110 mmHg);~16. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \>3 × the upper limit of normal (ULN); if ALT/AST is \>3 × ULN, the levels have been stable for 3 months and are \<5 × ULN;~17. Exposure to any investigational product within 4 weeks of randomization; or~18. Any condition or therapy which, in the opinion of the Investigator, might pose a risk to the subject or make participation in the study not in the subject's best interest.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 130 Years
- Healthy Volunteers: f

Study Arms:
- Epanova 2 g/day (Type: EXPERIMENTAL): Arm 1
- Olive Oil 2 g/day (Type: PLACEBO_COMPARATOR): Arm 2

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete